公开(公告)号：US20130345159A1

公开(公告)日：2013-12-26

申请号：US13996446

申请日：2011-12-21

Applicant: Andreas Kyas ,  Ernst Freund ,  Oliver Schlörke ,  Joerg Lill ,  Lars Rogall ,  Dario Menia ,  Gary Elliott ,  James Paterniti

Inventor： Andreas Kyas ,  Ernst Freund ,  Oliver Schlörke ,  Joerg Lill ,  Lars Rogall ,  Dario Menia ,  Gary Elliott ,  James Paterniti

IPC: C07H1/08 ,  C07C62/32 ,  C07H15/24

CPC classification number: C07C62/32 ,  A61K36/73 ,  A61K2236/333 ,  C07H1/08 ,  C07H13/08 ,  C07H15/24 ,  C07J63/008

Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).

Abstract translation: 从天竺葵的甲醇提取物获得心脏发生素主要异构体，并从其次要的异构体中分离。 两种异构体的分离可以通过手性相色谱法来实现，例如使用Chiralpak IC TM柱。 通过结晶可以进一步提高分离的心脏生长素主要异构体的纯度，产生在210nm处具有高达98.97％（a / a）的HPLC纯度的分离的心脏生长素主要异构体，效能为95.50％）（w / w）。

公开(公告)号：US1996197A

公开(公告)日：1935-04-02

申请号：US73785934

申请日：1934-07-31

Applicant: ERNST FREUND

Inventor： ERNST FREUND

IPC: D01F2/08

CPC classification number: D01F2/08

公开(公告)号：US20060020022A1

公开(公告)日：2006-01-26

申请号：US11187464

申请日：2005-07-22

Applicant: Brian Chekal ,  Ernst Freund ,  Charles Minard Grill ,  Elke Huthmann ,  Markus Juza ,  Vera Leshchinskaya ,  Mark Thomas Maloney ,  Lawrence Marvin Miller ,  Ying Wang ,  Ming Zeng

Inventor： Brian Chekal ,  Ernst Freund ,  Charles Minard Grill ,  Elke Huthmann ,  Markus Juza ,  Vera Leshchinskaya ,  Mark Thomas Maloney ,  Lawrence Marvin Miller ,  Ying Wang ,  Ming Zeng

IPC: C07D311/04 ,  A61K31/353

CPC classification number: C07B57/00 ,  B01D15/1814 ,  B01D15/1857 ,  B01D15/1864 ,  C07D311/04 ,  C07D311/58 ,  C07D335/06

Abstract: This invention relates to a method for separating enantiomers of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-1,2-dihydro-quinoline-3-carboxylic acid or ester, a substituted 2-trifluoromethyl-2H-thiochromene-3-carboxylic acid or ester, a substituted 3-trifluoromethyl-3,4-dihydro-naphthalene-2-carboxylic acid or ester, or a pharmaceutically acceptable salt of the acids or esters, using enantioselective fractional crystallization, enantioselective high performance liquid chromatography, enantioselective steady state recycling chromatography, or enantioselective multicolumn chromatography.

Abstract translation: 本发明涉及一种分离取代的2-三氟甲基-2H-色烯-3-羧酸或酯，取代的2-三氟甲基-1,2-二氢喹啉-3-羧酸或酯的对映异构体的方法， 2-三氟甲基-2H-二氢吡喃-3-羧酸或酯，取代的3-三氟甲基-3,4-二氢 - 萘-2-羧酸或酯，或其酸或酯的药学上可接受的盐，使用对映选择性分数 结晶，对映选择性高效液相色谱法，对映选择性稳态循环色谱法或对映选择性多色谱法。